HMNC Holding GmbH. (7/28/21). "Press Release: HMNC Brain Health Raises EUR 9 Million". Munich.

	Organisation	HMNC Holding GmbH (HMNC Brain Health)
	Group	HMNC (Holsboer / Maschmeyer) (Group)
	Organisation 2	MASCHMEYER Group (family Maschmeyer)
	Today	Alstin – Alternative Strategic Investment GmbH
	Product	antidepressant
	Product 2	venture capital
	Index term	HMNC–SEVERAL: credit, 202107 convertible debt financing €9m from renowned family offices incl Maschmeyer + Jahr + Gutmann
	Person	von Braunmühl, Benedikt (Rentschler 202309– CEO before HMNC Brain Health + Medicover AB + Qiagen + Chiron Vaccines)
	Person 2	Maschmeyer, Carsten (AWD)

Total Funds Raised to Date of EUR 28 Million From Prominent Investors Positions Company for Series B Round in 2021

HMNC Brain Health (“HMNC” or the “Company”), a biotech company pioneering the development of personalized therapies in psychiatry powered by predictive companion diagnostics, today announced it has received an additional EUR 9 million EUR from its current investors. The supplemental investment brings the total raised to date to EUR 28 million and will secure HMNC’s financial position in advance of an expected Series B round later this year.

The current raise, in the form of convertible debt, was provided by renowned family offices, including that of Carsten Maschmeyer, the Jahr family and Dr. Guntard Gutmann.

The additional funds will be used to accelerate HMNC’s pipeline development towards market maturity. In particular, the funding will allow the Company to prepare for two CRO-led proof-of-concept studies, drive strategic growth initiatives and strengthen the HMNC team.

“The continued support of our existing shareholders emphasizes their confidence in the strategic direction of the business and our potential to develop a unique pipeline in personalized, precision psychiatry,” said Benedikt von Braunmühl, CEO of HMNC Brain Health. “These funds will allow HMNC to advance our strategic agenda and take another step in improving the quality of lives of patients around the world suffering from depression or other neuropsychiatric disorders.”

Carsten Maschmeyer, Co-Founder and Member of the Board of Directors at HMNC Brain Health added, “We are extremely encouraged with the advancement of the clinical pipeline and will continue to support HMNC Brain Health on its way to become a leading player in precision psychiatry.”

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for HMNC (Holsboer / Maschmeyer) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)